GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Short Percentage of Float

Theranexus (XPAR:ALTHX) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Theranexus Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Theranexus's Short Percentage of Float

For the Biotechnology subindustry, Theranexus's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theranexus's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theranexus's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Theranexus's Short Percentage of Float falls into.


Theranexus (XPAR:ALTHX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALNFL XPAR:ALHYG XPAR:ALPAT XPAR:FALG XPAR:ALINT XPAR:ALVET XPAR:POXEL XPAR:ALBPS XPAR:ALMDP XPAR:ALQGC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
3VG:Germany
Address
60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
Website
https://www.theranexus.com
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines